- Revenue Outlook: Amgen has increased its full-year revenue forecast to a range between $35 billion to $36 billion, compared to the prior range of $34.3 billion to $35.7 billion. The previous estimate was $35.36 billion.
- Adjusted EPS Guidance: Expected adjusted earnings per share (EPS) is now forecasted between $20.20 to $21.30, an increase from the earlier range of $20 to $21.20. Previous estimates pegged EPS at $20.90.
- Capital Expenditure: Amgen maintains its capital expenditure target at approximately $2.3 billion, higher than the estimated $2.05 billion.
- Share Buyback Plan: The company is still planning for share buybacks up to $500 million.
- Tariff Impact: The 2025 guidance includes tariffs that have already been implemented. However, it does not account for tariffs or price changes announced but not yet implemented.
- Second Quarter Financial Results:
- Adjusted EPS for the second quarter of 2025 increased to $6.02 from $4.97 year-over-year, surpassing estimates of $5.26.
- Overall revenue growth was 9.4% year-over-year, reaching $9.18 billion, above the $8.91 billion estimate.
- Key Product Sales Highlights:
- Repatha revenue surged by 31% year-over-year to $696 million, exceeding the $673.4 million estimate.
- Evenity revenue rose 32% to $518 million, beating the $486.9 million estimate.
- Prolia revenue fell 3.7% to $1.12 billion against the $1.08 billion estimate.
- Uplizna revenue saw a significant increase of 91% to $176 million, well above the $122.3 million estimate.
- Tavenos revenue increased 55% to $110 million, surpassing the $100.7 million estimate.
- Product and Pipeline Developments:
- The Phase 2 trial of MariTide for chronic weight management is ongoing, with part 2 results expected in the fourth quarter of 2025.
- Two Phase 3 trials for MariTide, targeting different obesity-related indications, are currently enrolling patients.
- Amgen has started Phase 3 cardiovascular and heart failure trials, with an obstructive sleep apnea trial planned for late 2025.
- Operational Efficiency:
- Adjusted operating expenses rose by 8.2% year-over-year to $4.89 billion, slightly below the $4.94 billion estimate.
- Adjusted research and development costs increased 18% to $1.69 billion, close to the $1.71 billion estimate.
- Adjusted selling, general and administrative expenses decreased by 2.1% year-over-year to $1.65 billion, under the $1.68 billion estimate.
Amgen Inc on Smartkarma
On Smartkarma, independent analysts like Baptista Research are providing valuable insights into Amgen Inc, a leading biotechnology company. In one report titled “Amgen Inc.: What Is Its Commercial Strategy For UPLIZNA In New Indications?”, Baptista Research highlights Amgen’s strong first-quarter performance in fiscal year 2025. The company experienced a notable revenue increase of 9% year over year, driven by a 14% volume growth across its product portfolio. Success in various categories like general medicine, rare disease, inflammation, and oncology indicates successful market penetration and increasing patient adoption.
Another report by Baptista Research, “Amgen’s Big Bet on Obesity: Is This the Pharma Giant’s Next Breakout Moment?“, sheds light on Amgen’s rapid emergence in the obesity drug market. With the investigational drug MariTide showing promising Phase II results of up to 20% weight loss with monthly dosing, Amgen is strategically positioned to tap into the lucrative $100 billion market by 2030. With two Phase III trials targeting diabetic and non-diabetic patients underway, Amgen is poised for potential growth and market share expansion in the pharmaceutical industry.
A look at Amgen Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Amgen Inc. is positioned for favorable long-term prospects based on the Smartkarma Smart Scores analysis. With solid scores in Dividend, Growth, Resilience, and Momentum, the company demonstrates strength across key areas. The high Dividend score suggests a stable payout to investors, while the Growth and Resilience scores indicate potential for sustainable expansion and ability to withstand market challenges. Additionally, the Momentum score reflects positive market sentiment and indicates a promising future trajectory for Amgen Inc.
Amgen Inc. is an independent biotechnology medicines company specializing in human therapeutics. Focused on developing innovative treatments for serious illnesses, the company leverages advancements in cellular and molecular biology to create impactful medicines. The company’s robust performance across various Smartkarma Smart Scores factors positions it well for continued success in the dynamic biotechnology industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
